192 results about "Lung tumor" patented technology

Embodiments herein provide a non-invasive tracking system that accurately predicts the location of tumors, such as lung tumors, in real time, while allowing patients to breathe naturally. This is accomplished by using Electrical Impedance Tomography (EIT), in conjunction with spirometry, strain gauge and infrared sensors, and by using sophisticated patient-specific mathematical models that incorporate the dynamics of tumor motion. With the direction and speed of lung tumor movement successfully tracked, radiation may be effectively delivered to the lung tumor and not to the surrounding healthy tissue, thus increased radiation dosage may be directed to improving local tumor control without compromising functional parenchyma.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

The invention provides a lung tumor recognition system and method based on a convolutional neural network. The lung tumor recognition method based on the convolutional neural network includes the steps that multiple cascading images collected along a preset dimensionality are received; the cascading images are blocked according to the rule that moving is the same in the same window, the image blocks in the cascading images corresponding to the same window position are combined and convolved to obtain feature image blocks, and down-sampling is conducted on each feature image block; the feature image blocks subjected to down-sampling are subjected to up-sampling; a heat degree prediction map is drawn on the basis of probability that each pixel in the heat degree prediction map corresponds to at least one feature image block subjected to up-sampling may be true or false. The system and method effectively increase the recognition rate of local areas of the cascading images with spatial association.

The invention relates to a dry powder inhalation with low-density or ultralow-density inhalable medicinal powder, a method for preparing the dry powder inhalation and application of the dry powder inhalation in preparing medicament for treating tumor, in particular lung tumor. The dry powder inhalation can deliver the tumor medicament to the lung directly so as to improve the medicament effect andreduce side effect; and the 'foaming' technology adopted for preparing the dry powder inhalation optimizes the micromeritic properties of the medicinal powder, and greatly improves the deposition performance of the tumor medicinal dry powder inhalation. The dry powder inhalation, the preparation method and the application thereof are also suitable for preparing non-vector dry powder inhalation toovercome the defects of uneven mixture between medicament and vector easily occurring in the dry powder inhalation.

A method and system for detecting tumors and nodules in a lung tissue are provided. The method includes the steps of (a) providing a plurality of asymmetric templates of at least one 3D appearance model of a nodule; (b) providing a 3D imaging data set of the entire area of a tissue; (c) matching the 3D imaging data set of the entire area of the tissue with each of the plurality of asymmetric templates to search for 3D objects in the tissue that match the at least one 3D appearance model; (d) determining the volume of the 3D objects found in the tissue; and (e) providing an output representing 3D objects that match the 3D appearance model.

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.

The invention provides a correlation analysis method based on CT imaging characteristics and prognosis survival conditions of non-small cell lung cancer patients, and belongs to the field of computeraided medicine. The method comprises the following steps: firstly, carrying out segmentation and feature extraction and optimization on lung tumors; And then, combining the tumor imaging characteristics with the survival condition of the patient through a machine learning method, constructing a prognostic evaluation model of the non-small cell lung cancer to predict the prognostic survival condition of the patient, and designing an experiment to evaluate the performance of the prognostic analysis model. The invention provides a new scheme for exploring the relationship between the imaging characteristics and the prognostic survival condition of the patient.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human and mouse secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from mouse bone marrow and human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, placental, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

The invention relates to a novel lung tumor locating needle. The novel lung tumor locating needle comprises a puncture needle, anchoring locating needles, a locating line and a pushing device, wherein the puncture needle is composed of a puncture needle cannula and a puncture needle handle, the pushing device comprises a pushing tube and a pushing tube handle, the pushing tube is arranged in the puncture needle cannula, the far end of the pushing tube abuts against the near ends of the anchoring locating needles, the width of the near ends of the anchoring locating needles is larger than or equal to the outer diameter of the pushing tube, the far end of the locating line is connected with the near ends of the anchoring locating needles, the locating line extends out of the exterior of the pushing device from the interior of a tube cavity of the pushing tube, the far end of the locating line is provided with multiple colored bands with different colors, and the length of each colored band ranges from 3 mm to 15 mm. According to the novel lung tumor locating needle, the functions of determining lesion localization and measuring the depths of lesions are achieved simultaneously, the lung or parts of the lung can be lifted up, excision of the lesions is convenient for a surgeon, and the depths of the lesions can be measured during an operation.

Compositions and methods for the diagnosis of lung cancer are disclosed. Such methods are useful to detect early tumors or provide adequate stage / grade information or tumor specificity. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Such compositions may be used, for example, to improve lung cancer diagnosis and prognosis and potentially differentiate between NSCLC and SCLC.

The invention discloses a specific culture medium for a lung tumor organ and a stentless 3D culturing method. The specific culture medium is prepared from the following components: FBS, double antibody, N-2, Noggin, B-27, EGF, FGF-10, Y-27632, A 83-01, SB202190, N-acetylcysteine, HEPES, Glutamax, IGF-1, hydrocortisone and Advanced DMEM / F12. The culturing method comprises the following steps: adding a tumor cell into a low serum culture medium, re-suspending the tumor cell, inoculating the tumor cell into a culture vessel, adding the specific culture medium into the culture vessel, changing thespecific culture medium once a day, and performing culturing until an organoid is formed. According to the culture medium and culturing method, a tumor organoid can quickly generate, can be stably cultured for a long time, is regular in spheroid form and has uniform and controllable size, and the heterogeneity of a tumor tissue of a patient can be well maintained in vitro.

Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and / or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.

The invention relates to exosome as well as a preparation method and application thereof in preparing medicines for treating lung cancer. The preparation method comprises a step of stimulating cells to secrete the exosome by using KRN7000 and ATP (Adenosine Triphosphate). By adopting the preparation method provided by the invention, efficient in-vitro exosome preparation can be achieved. The invention further provides the exosome prepared by using the method. The exosome has relatively good cytotoxic effects and lung tumor resistance activity. The invention further provides application of the exosome in preparing medicines for treating lung cancer.

Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and / or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

The invention discloses a method for constructing a benign and malignant lung tumor prediction model. The method comprises the following steps that (1) a lung tumor patient sample is selected and computerized tomography (CT) is performed on the lung region of the lung tumor patient so as to acquire the corresponding CT image; (2) the CT image acquired in the step (1) is sketched and the lung lesion region is segmented so as to obtain the marked lesion region; (3) quantitative image features are extracted from the marked lesion region; (4) feature selection is performed by using the Lasso algorithm; and (5) the selected feature data act as the input, parameter optimization is performed on Logistic regression by using the gradient descent algorithm and finally the benign and malignant lung tumor prediction model is obtained by using Logistic training. The method for constructing the benign and malignant lung tumor prediction model is simple, short in time consumption and high in accuracyof the prediction model and can be applied to qualitative diagnosis of the benign and malignant lung tumors.

The invention relates to a dry powder inhaler with a constituent rubescensin A as well as a preparation method and application thereof. The dry powder inhaler is a medicinal composition formed by mixing the constituent rubescensin A as an active constituent with pharmaceutically acceptable excipients. Compared with orally administrated medicines, the dry powder inhaler developed by using the technical scheme provided by the invention greatly improves the effect of the constituent rubescensin A on treating esophagus cancers, lung tumors and leukemia.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

The invention provides a rapid detection kit for a lung cancer marker GK5 in exosome and belongs to the technical field of kits. The kit contains an exosome in-situ capturing pore plate, wherein eachpore in the exosome in-situ capturing pore plate contains a fluorescein-labeled molecular beacon; the molecular beacon is a specific DNA (Deoxyribonucleic Acid) probe of targeting tumor marker GK5 mRNA (micro Ribonucleic Acid). The kit provided by the invention applies an exosome in-situ capturing pore plate technology and is used for detecting the tumor marker GK5 mRNA in a body fluid sample of alung cancer patient; the kit can be used for carrying out early diagnosis on medical clinical lung tumors. The technology is a third-generation body fluid biopsy technology based on exosome detection, has the advantages of non-invasive or minimally invasive effect, ultrahigh sensitivity, rapidness, specificity and the like and is applicable to molecular diagnosis and epidemiological survey of themedical clinical lung tumors.

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human and mouse secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from mouse bone marrow and human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, placental, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

The invention offers two sets of tumor-dissolving recombination adenovirus. One set is produced by rite-directed mutagenesis in virus E1A gene. The other set produced by replacing E1A promoter with tumor specificity promoter. The fiber end of parts of the recombination adenovirus is added RGD short peptide. And parts of are carried HSV1-tkm. It is proved by experiment that the two sets of virus can strongly infect tumor cell, do a great deal replication and breeding, and finally dissolve cell. The released filial generation adenovirus can infect around tumor cell again. Thus dosage effect and against cancer capability of virus gene can be enlarged by breeding infecting cycle. The tow sets of tumor-dissolving recombination adenovirus appearances strong against cancer effect in animal subcutaneous, human liver and lung tumor model test.

The invention, which belongs to the medical equipment technology field, relates to a respiratory gating indication method used for radiotherapy and an apparatus thereof. The method comprises the following steps that: a remote controller that includes a CPU microprocessor, an arrangement key, control keys, a liquid crystal display, an infrared remote controlled coding circuit and an emitting device of the circuit is arranged; an infrared reception and decoding circuit, a second CPU microprocessor, an auxiliary LED indicating lamp and a nixie tube display are arranged; an indicator comprising a third CPU microprocessor, a drive circuit, a main LED indicating lamp and a sounder is arranged; and a power source is arranged. According to the invention, clear light and sound indication can be provided for a patient; therefore, an influence of a respiratory movement can be effectively reduced; localization precision of thoracic-abdominal tumor radiation therapy target region can be substantially improved; unnecessary irradiation on a normal organ and a normal part can be effectively avoided; and occurrences of phenomena of damage and necrosis of normal cells can be avoided or reduced. Besides, the apparatus is cheap and can be applied conveneitnly. Moreover, the method and the apparatus can be widely applied to radiation therapy of several kinds of tumors like a thoracic tumor, an abdominal tumor, a lung tumor, a liver tumor, a renal tumor and a breast tumor and the like.

Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

The invention relates to the technical field of 4DCT image reconstruction, in particular to a reconstruction method, a medium and a device for reconstructing a special image for performing image omicsfeature extraction based on a lung tumor 4DCT image. The objective of the invention is to solve the problem of how to extract iconomics characteristic parameters close to a static CT image from a reconstructed image of a 4DCT image and how to influence modeling of a prediction model by the iconomics characteristic parameters. A concept and a mathematical model (MGDPM) for reconstructing an imageon the basis of a minimum gradient density projection matrix are provided by analyzing the time domain gradient of a tumor centroid motion curve, and the concept and the mathematical model are used for reconstructing the image on the basis of the minimum gradient density projection matrix. Compared with the existing traditional average density projection, the invention provides the prediction capability of MIP (Maximum Intensity Projection) image extraction characteristics in NSCLC (Non-Small Cell Lung Cancer) early metastasis, in particular to a prediction capability of MIP (Maximum IntensityProjection) image extraction characteristics in NSCLC early metastasis.

Provided are methods of treating lung cancer in a patient in need thereof. The method includes administration to the patient a composition comprising a therapeutically effective amount of a compound that reduces the expression level of E3 ubiquitin-protein ligase MDM2. The compound in certain instances is a miR-660 miRNA, or a functional variant thereof. The patient in need of treatment in certain instances expresses miR-660 in a lung tissue sample or biological fluid sample at a level lower as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof, that have been given a favorable prognosis; expresses MDM2 at a higher level in a lung tissue sample or biological fluid sample as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof that have been given a favorable prognosis; and / or expresses p53 in a lung tissue sample or a biological fluid sample below a control level derived from a lung tumor tissue sample, or plurality thereof, or a biological fluid sample, or plurality thereof, obtained from a patient that has a favorable lung cancer prognosis; or a control level derived from a healthy subject.